Mensinorm Set

Follicle-Stimulating Hormone; Luteinising Hormone, the active ingredient in Mensinorm Set, is a gonadotropin presented as an injectable solution for subcutaneous use. It is used to treat infertility related to anovulation, to support controlled ovarian stimulation in assisted reproductive technology, and to manage hypogonadotropic hypogonadism.

GNH USA supplies Mensinorm Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Mensinorm Set, a gonadotropin preparation, is employed in reproductive medicine to stimulate ovarian function.

Infertility due to anovulation: promotes follicular growth to enable ovulation. Controlled ovarian stimulation for assisted reproductive technology: enhances multiple follicle development for IVF cycles. Hypogonadotropic hypogonadism: replaces deficient gonadotropins to restore normal ovarian activity.

Adverse reactions to Mensinorm Set are reported primarily at the injection site and systemically.

Common Side Effects: - Injection site pain or erythema - Mild abdominal discomfort or bloating - Nausea or mild headache - Transient ovarian hyperstimulation (mild) - Fatigue or dizziness

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome (OHSS) - Multiple pregnancy (high-order twins or more) - Allergic reaction including anaphylaxis - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Ectopic pregnancy

When using Mensinorm Set, clinicians should observe several safety measures.

Assess ovarian response before initiation: perform baseline ultrasound and hormone levels. Monitor estradiol concentrations: adjust dose to avoid excessive stimulation. Avoid use in uncontrolled thyroid or adrenal disorders: stabilize endocrine status first. Exercise caution in patients with ovarian cysts or polycystic ovary syndrome: risk of OHSS may be higher. Discontinue if hypersensitivity reaction occurs: stop treatment and provide appropriate care. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mensinorm Set may interact with other agents that influence ovarian activity or coagulation.

Major Interactions (Avoid): - Concurrent use of other gonadotropins (e.g., hCG) that markedly increase OHSS risk. - High‑dose estrogen therapy: may exacerbate ovarian hyperstimulation. - Anticoagulants in patients predisposed to thrombosis: increased clotting risk.

Moderate Interactions (Monitor Closely): - GnRH agonists or antagonists used in IVF protocols: require dose adjustment. - Corticosteroids that alter hormone metabolism: monitor estradiol levels. - Thyroid hormone replacement: ensure euthyroid status before stimulation.